Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Toripalimab and Chemotherapy in Locally Advanced OSCC
NCT04473716Phase 1Completed
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Jul 2020
- Primary completion
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of toripalimab in oral squamous cell carcinoma (OSCC), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoints: Major Pathological Response at 1 year and Safety and Adverse Events at 1 year. Started Jul 2020; status: completed.
02
Drugs
toripalimab
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT04473716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04473716.